Introduction

Joint wear is a tough challenge because cartilage has a very limited ability to heal itself. If you are considering your options, the most practical question is usually not which treatment sounds most advanced, but which treatment matches the nature and extent of your joint problem. This article explains the ChondroFiller injection — what it is, how it works, which patients tend to be most suitable, and how it differs from a surgical cartilage repair — so that you can approach a consultation with realistic expectations.

What Is ChondroFiller and How Does It Work?

ChondroFiller is a Class III CE-marked medical device: an injectable, acellular (cell-free) type I collagen hydrogel scaffold made by Meidrix Biomedicals, Germany, and imported into the UK under prescription. When delivered into a joint, the liquid collagen component mixes and self-gels within a few minutes, filling the contour of the worn area. The result is a porous three-dimensional matrix that stays in place without sutures or fixation.

The gel is not simply a filler or lubricant. As a collagen-based scaffold, it is designed to act as a chemotactic matrix — attracting the patient's own progenitor cells from the surrounding synovium and subchondral bone marrow into the defect site. Over the following months these cells populate the scaffold, and over one to two years the collagen is gradually resorbed and replaced by the patient's own repair tissue. Published clinical data report International Knee Documentation Committee (IKDC) scores improving by approximately 30 points over 12 to 36 months in knee studies, and modified Harris Hip Scores (mHHS) improving by over 30 points in hip studies.

How to Think About It

Rather than acting as a simple glue or a passive cushion, ChondroFiller adds a biologically active protective layer that supports the joint surface and may encourage tissue repair. Its gel can absorb load and adapt to the forces inside a joint. Because it is collagen-based, it has genuine biological potential — but it is best understood as a supportive, joint-preserving injection rather than a guaranteed cartilage repair, a cure, or a reversal of arthritis. Benefits vary between individuals.

It is also important to understand that the ChondroFiller injection is the non-surgical delivery pathway. It is performed as an outpatient procedure under ultrasound guidance, with no theatre, no incision, and no general anaesthetic. This distinguishes it clearly from the Liquid Cartilage procedure, which is a separate surgical protocol (discussed further below).

Clinical Evidence

The device carries a strong safety profile. Across more than 19,000 units sold since 2013, no serious incidents have been reported in the manufacturer's clinical evaluation data. Clinical studies report a near-zero rate of complications. A 2023 study of thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength following ChondroFiller treatment (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023). Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) imaging in published series shows scores of around 80 and above, indicating high-quality tissue regeneration and defect fill. These findings relate to the device and its application, and responses vary between patients.

When the Injection Is Appropriate — and When Surgery May Be Better

The ChondroFiller injection tends to suit patients who have accessible lesions, smaller joints, or early-to-moderate cartilage defects where a non-surgical approach is clinically appropriate. It also suits those for whom surgery carries additional risk, or those who prefer to exhaust non-surgical options first. The decision turns on the size and location of the defect, the degree of existing joint wear, and the patient's overall health and activity goals.

For larger or load-bearing defects — particularly in the knee, hip, shoulder, or ankle — a surgical approach may achieve more durable results. The Liquid Cartilage procedure (also called the Lee Liquid Cartilage Protocol, or LLC Protocol) is a distinct, keyhole arthroscopic surgical technique developed by Professor Paul Y. F. Lee. It is not an injection and should not be confused with the ChondroFiller injection. In the LLC Protocol, ChondroFiller scaffold is placed directly into the prepared defect during surgery, alongside biological adjuncts such as platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and — where indicated — the patient's own mesenchymal stem cells (MSCs) from bone-marrow concentrate or micro-fragmented fat. This surgical pathway involves theatre, anaesthetic, and a structured rehabilitation programme. It is the appropriate discussion for patients whose defect size or joint characteristics place them beyond the scope of an outpatient injection.

Practical Considerations and Limitations

A key advantage of the ChondroFiller injection is its minimally invasive, non-surgical delivery, with a straightforward recovery. There is no incision and no general anaesthetic. However, results vary between individuals, and benefits cannot be guaranteed. The injection is not a cure for osteoarthritis, and it is not appropriate for all patients or all joints. A thorough assessment — including imaging and clinical examination — is necessary before any treatment decision is made. Further research into long-term outcomes continues.

Conclusion

ChondroFiller is best understood as a non-surgical, supportive collagen injection that adds a biologically active, protective layer to a worn joint surface. It may help appropriately selected patients, but it is not a cure, and results depend on individual factors including defect size, location, and overall joint health. For patients with more complex or larger defects, the Liquid Cartilage keyhole surgical procedure is a separate and distinct option to explore. At the London Cartilage Clinic, a specialist assessment can clarify which pathway — injection or surgery — is the more appropriate starting point for your joint.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.